Physiological and Biomechanical Data Collection Study in Epilepsy Subjects
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to gather changes in physiological and biomechanical data during daily activity and sleep in epilepsy subjects.
Condition or disease
The purpose of this study is to gather changes in physiological and biomechanical data such as ECG, respiration, and accelerometry data during daily activity and sleep in pediatric and adult subjects with epilepsy. Subjects will use a device that enables monitoring of the human state in everyday, free-living environments.
To gather changes in physiological and biomechanical data in epilepsy subjects [ Time Frame: 72 hours ]
The E-32 study was designed to capture the subject's physiological and biomechanical data such as ECG data and rate, respiratory data and rate, and body orientation, motion and movement (accelerometry) during typical events such as walking, sitting, running and sleeping in order to help build a database of stereotypical human activity.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
6 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult and pediatric epilepsy patients willing to provide physiological and biomechanical data
Subject must be six (6) years of age or older
Subject has a clinical diagnosis of epilepsy
Subject is currently taking at least one antiepileptic medication.
Subject must be in good general health and fully ambulatory.
Subject or guardian must be willing and able to complete informed consent and/or assent for children and HIPAA authorization.
Subjects with chest circumference smaller than 29 inches or greater than 47 inches.
Subjects with existing signs of skin irritation, rash, damage or infection on the torso that in the opinion of the investigator would prevent the subject's participation in the study.
Subjects with a medical condition that in the opinion of the investigator would affect his/her ability to participate in the study.
Subjects with implanted defibrillators, pacemakers or neurostimulators (e.g., vagus nerve stimulators or pain stimulators).
Subjects who are pregnant or lactating.
Subjects with severe psychiatric disease that in the opinion of the investigator would prevent the subject's successful completion of the study.
Subjects 6 to 16 years of age with moderate/severe learning difficulties or those who may be at risk of self-harm.
Subjects prescribed drugs specifically for a cardiac or autonomic disorder that in the investigator's opinion would affect heart rate response unless the patient has ictal tachycardia while taking said drugs. These include, but are not limited to, beta adrenergic antagonists ("beta blockers").
Subjects with cardiovascular arrhythmias or cardiac disease that would preclude the ability to detect intrinsic changes in heart rate due to activity, stress, or seizure. This would include but not be limited to chronic atrial fibrillation or chronotropic incompetence.
Subjects with a history of dependence on alcohol or narcotic drugs within the past 2 years as defined by DSM IV-R.
Subjects currently participating in another clinical study.